SCHEMBL24251084

SCHEMBL24251084

Cc1ccc(NC(=O)c2ccc(C3CCCCN(C)C3)cc2)cc1Nc1nccc(-c2cnccn2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 18/20 0.55
KIT P10721 13/20 0.55
BCR P11274 12/20 0.55
PDGFRB P09619 8/20 0.55
PDGFRA P16234 8/20 0.55
EGFR P00533 2/20 0.55
ABL2 P42684 2/20 0.55
PLK4 O00444 1/20 0.55
DDX3X O00571 1/20 0.55
GAK O14976 1/20 0.55
SLC22A2 O15244 1/20 0.55
MAPK13 O15264 1/20 0.55
CA12 O43570 1/20 0.55
SLC22A3 O75751 1/20 0.55
ABCB11 O95342 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
LMNA P02545 1/20 0.55
ALB P02768 1/20 0.55
RAF1 P04049 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29551281 1.00 ABL1 (0.55) ABL1KITBCRPDGFRBPDGFRA
SCHEMBL24251092 0.91 ABL1 (0.68) ABL1KITBCRPDGFRBPDGFRA
SCHEMBL29551209 0.91 ABL1 (0.68) ABL1KITBCRPDGFRBPDGFRA
SCHEMBL29551533 0.88 ABL1 (0.51) ABL1KITBCRPDGFRBPDGFRA
SCHEMBL24250928 0.88 ABL1 (0.51) ABL1KITBCRPDGFRBPDGFRA
SCHEMBL28709207 0.87 ABL1 (0.62) ABL1KITBCRPDGFRBPDGFRA
SCHEMBL24250957 0.87 ABL1 (0.69) ABL1KITBCRPDGFRBPDGFRA
SCHEMBL29551194 0.87 ABL1 (0.69) ABL1KITBCRPDGFRBPDGFRA
SCHEMBL24251040 0.86 ABL1 (0.63) ABL1KITBCRPDGFRBPDGFRA
SCHEMBL29552046 0.86 ABL1 (0.63) ABL1KITBCRPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers HONGYI & ASS LLC (US) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers SNCA, NGF, SLC18A2 ABL1 695/4885KIT 2333/4885BCR 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.